Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 9, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/jpm9010001
Keywords
read-through; exon skipping; vector-mediated gene therapy; cell therapy
Funding
- Japan Society for the Promotion of Science [18K07544, 28-6]
- Japan Agency for Medical Research and Development [18ek0109239h0002, 18lm0203066h0001, 18lm0203069h0001]
- Grants-in-Aid for Scientific Research [18K07544] Funding Source: KAKEN
Ask authors/readers for more resources
Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle weakness, is caused by the absence or a decreased amount of the muscle cytoskeletal protein dystrophin. Currently, several therapeutic approaches to cure DMD are being investigated, which can be categorized into two groups: therapies that aim to restore dystrophin expression, and those that aim to compensate for the lack of dystrophin. Therapies that restore dystrophin expression include read-through therapy, exon skipping, vector-mediated gene therapy, and cell therapy. Of these approaches, the most advanced are the read-through and exon skipping therapies. In 2014, ataluren, a drug that can promote ribosomal read-through of mRNA containing a premature stop codon, was conditionally approved in Europe. In 2016, eteplirsen, a morpholino-based chemical capable of skipping exon 51 in premature mRNA, received conditional approval in the USA. Clinical trials on vector-mediated gene therapy carrying micro- and mini-dystrophin are underway. More innovative therapeutic approaches include CRISPR/Cas9-based genome editing and stem cell-based cell therapies. Here we review the current status of therapeutic approaches for DMD, focusing on therapeutic approaches that can restore dystrophin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available